Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

April 15, 2021 Auto Bot Boehringer Ingelheim, collaboration, Expand, lung cancer, MD Anderson, Pharma, Targeted Therapies 0

Shots:

  • Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC
  • The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC
  • The expanded agreement allows the partners to expand their lung cancer indication programs targeting KRAS and TRAILR2, including Boehringer Ingelheim’s BI 1701963, BI 1823911, BI 3011441, along with bi-specific TRAILR2 agonist

Click here to­ read full press release/ article | Ref: Business Wire | Image: Twitter

The post Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer first appeared on PharmaShots.